Home>Topics>Stocks>Arena Pharmaceuticals

Arena Pharmaceuticals ARNA

  1. All
  2. Commentary
  3. Stock Reports
  4. Headlines
    1. Arena Conference Call Sets Stage For Near Term Equity Movement

      Headlines

      Mon, 28 Jul 2014

      By Spencer Osborne : Arena Pharmaceuticals (NASDAQ: ARNA ) will be hosting its quarterly conference call on Friday, August 1st, 2014 at 8:00 AM Eastern time. This particular call

    2. Arena Sees Belviq Sales Climb Despite Seasonality

      Headlines

      Fri, 25 Jul 2014

      By Spencer Osborne : Sales of the anti-obesity drug, Belviq, from Arena Pharmaceuticals (NASDAQ: ARNA ) seem to be trying to buck the trend in seasonality in the anti-obesity sector. As a relatively new product on the market

    3. After Hour Gainers / Losers

      Headlines

      Mon, 21 Jul 2014

      Top gainers, as of 5:15 p.m.: SANM +9.2% . TQNT +7.0% . SNTA +5.4% . APA +4.5% . ARNA +2.1% . Top losers, as of 5:15 p.m.: UCTT -9.4% . RMBS -3.6% . OTCQB:GSAT -2.2% . CTRP -1.4% . TWX -1.3% . Post your comment!

    4. Arena secures Belviq distribution in Israel

      Headlines

      Mon, 21 Jul 2014

      Arena Pharmaceuticals ( ARNA -1.4% ) subsidiary Arena Pharmaceuticals GmbH enters into an exclusive marketing and supply agreement with Teva Pharmaceuticals' local subsidiary Abic Marketing Ltd. to market and distribute Belviq in Israel for

    5. Arena Stock Rises With Expected Jump In Belviq Sales

      Headlines

      Fri, 18 Jul 2014

      This week, we saw an anticipated pop in prescription numbers for the anti-obesity pill Belviq from Arena Pharmaceuticals (NASDAQ: ARNA ). A nice week-over-week climb was expected, considering that the last data we saw fell in the week

    6. Arena Gives Pipeline Exposure - Is The Company Partner Shopping?

      Headlines

      Wed, 16 Jul 2014

      By Spencer Osborne : Arena Pharmaceuticals (NASDAQ: ARNA ) has announced that it was granted U.S. Patent No. 8,778,950 , entitled "Cannabinoid Receptor Modulators" by the United

    7. Arena Stock Holds On Expected Dip In Sales - Bottom May Be In

      Headlines

      Fri, 11 Jul 2014

      By Spencer Osborne : The timing is not great, but the reality is that the prescription numbers this week showed an expected dip because they included the 4th of July Holiday. That is little consolation for longs that saw the equity suffer a 10% dip when the announcement of the sale of shares by CEO

    8. Eisai Metabolic sales force now 600

      Headlines

      Thu, 10 Jul 2014

      Arena Pharmaceuticals ( ARNA ) reports that Eisai has added 200 new contract sales reps in its Metabolic Business Unit. The total number of sales people promoting

    9. Arena Prescription Sales OK - CEO Sales Are Not

      Headlines

      Mon, 7 Jul 2014

      By Spencer Osborne : Sales of Arena Pharmaceuticals ( ARNA ) prescription anti-obesity drug Belviq are in and are okay this week. However, the focus of the week has shifted from script

    10. Arena chief's stock sale invites criticism

      Headlines

      Mon, 7 Jul 2014

      about Belviq's prospects by Arena Pharmaceuticals ( ARNA -8.4% ) CEO Jack Lief has ..... large portion of his holdings of ARNA stock. Mr. Lief felt compelled ..... Q2 2013's debut of $1.3M. ARNA 's stock is down 60% from its

    « Prev12345Next »
    Content Partners